New research is changing what we know about breast, lung, and prostate cancers. On Thursday, October 1, the Alliance for Clinical Trials in Oncology will host a public webinar highlighting key findings from Alliance and Alliance Foundation Trials (AFT) studies presented at the 2026 American Society for Clinical Oncology (ASCO) Annual Meeting.
“We are excited to showcase the high-profile research findings that several Alliance researchers presented at the 2026 ASCO Meeting,” said Evanthia Galanis, MD, DSc, Group Chair of the Alliance and Sandra J. Schulze Professor of Novel Therapeutics and Professor of Oncology at the Mayo Clinic. “Supported by funding from the National Cancer Institute and with the momentum from our industry collaborations, we’re able to advance discoveries and make meaningful improvements in cancer care for the benefit of patients everywhere.”
“Clinical trials conducted by Alliance researchers have meaningfully shaped cancer care, often resulting in new standards of care and FDA approval of new treatments,” said Olwen Hahn, MD, Director and Principal Investigator of the Alliance Central Protocol Operations Program and an Associate Professor of Medicine at the University of Chicago Medical Center. “During this 60-minute webinar, our panel of investigators will explain how the latest research results are impacting cancer care. We are also proud to have patient representatives join our webinar to help explain the significance of the findings for people living with cancer and their loved ones.”
Panelists include:
In addition to the investigators, patient representatives from the Patient Alliance Committee will join the panel to comment specifically on the importance of each trial and provide insight into the patient’s perspective.
The webinar is free and open to the public. Registration is now open .
# # #
Alliance Foundation Trials, LLC, is a research organization that develops and conducts cancer clinical trials, working closely with the Alliance for Clinical Trials in Oncology scientific investigators and institutional member network, research collaborators, and non-NCI funding sources. AFT seeks to fulfill the vision of the Alliance for Clinical Trials in Oncology to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer. Current AFT studies are funded by industry collaborators and the Patient-Centered Outcomes Research Institute (PCORI).
The Alliance for Clinical Trials in Oncology is a national leader in advancing cancer research, uniting more than 26,000 cancer specialists at 112 main institutions and 1,400 affiliates across the U.S. and Canada. As part of the National Clinical Trials Network and a leading research base for the NCI Community Oncology Research Program, the Alliance conducts pioneering, practice-changing clinical trials that improve outcomes and reshape standards of care. Our work has led to multiple FDA approvals, influenced national guidelines, and produced hundreds of high-impact publications. More than 40,000 participants have taken part in Alliance studies, and our growing biospecimen repository now includes more than 1.5 million samples, collected over the past 30 years. Learn more at AllianceforClinicalTrialsinOncology.org .